Exelixis Archives -

Exelixis’ Cabometyx misses survival target in liver cancer trial

https://pharmaphorum.com/news/exelixis-cabometyx-misses-survival-target-in-liver-cancer-trial/

Merck gets a leg-up for Keytruda in first-line kidney cancer

https://pharmaphorum.com/news/merck-gets-a-leg-up-for-keytruda-in-first-line-kidney-cancer/

Exelixis takes $20m option Iconic/Zymeworks’ cancer ADC

https://pharmaphorum.com/news/exelixis-takes-20m-option-iconic-zymeworks-cancer-adc/

FDA kicks off review of second kidney cancer combo based on BMS’ Opdivo

https://pharmaphorum.com/news/fda-starts-review-of-second-kidney-cancer-use-for-bms-opdivo/

Exelixis doubles down on ADCs for cancer with NBE, Catalent deals

https://pharmaphorum.com/news/exelixis-doubles-down-on-adcs-for-cancer-with-nbe-catalent-deals/

BMS gets an important win for Opdivo combination in kidney cancer

https://pharmaphorum.com/news/bms-gets-an-important-win-for-opdivo-combination-in-kidney-cancer/

Exelixis’ Cabometyx approved in second-line liver cancer in US

https://pharmaphorum.com/news/exelixis-cabometyx-approved-in-second-line-liver-cancer-in-us/

Ipsen/Exelixis’ drug approved in EU for kidney cancer

https://pharmaphorum.com/news/ipsenexelixis-drug-approved-eu-kidney-cancer/

Search